To what extent did device adherence play a role in the clinical endpoints with TRIDENT?
Are there ways to support patient adherence and tolerability during concurrent chemoradiation, which would potentially improve efficacy with Early-Start in certain patients?
This question is part of our ASTRO 2026 collaboration, inspired by the LBA Session Presentation "TRIDENT: Phase 3 Trial of Tumor Treating Fields (TTFields) Therapy Concurrent with Temozolomide (TMZ) for Newly Diagnosed Glioblastoma (NDGBM)" by Dr. Wenyin Shi, MD, PhD
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Thomas Jefferson University Hospital
Answered on
TTFields is a patient-directed therapy, and adherence directly affects how much treatment a patient actually receives. In TRIDENT’s post hoc analysis pooling both treatment arms, patients with at least 50% device usage, averaged over the first three months after TTFields initiation, had longer media...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · University of California San Diego
Answered on
The authors report that a quarter of patients on both arms did not initiate maintenance TTF. Adherence is a major burden of this therapy, and in a non-sham-controlled study, intention-to-treat is the correct way to analyze the outcomes. Based on ITT, there was no significant survival benefit. I’m su...
Join for free or sign in to see the full answer